Astellas Entered into an Exclusive License Agreement with Kate Therapeutics to Develop and Commercialize KT430
Shots:
- KateTx will receive up front & is also eligible to receive development, regulatory and commercial milestones along with royalties on worldwide sales. Astellas to get an exclusive license globally to develop, manufacture and commercialize KT430
- The agreement will combine Astella's depth of experience and KateTx's unique scientific approach to developing gene therapies for X-linked myotubular myopathy (XLMTM) patients along with the AT132 program
- KT430, a preclinical next-generation investigational gene therapy that uses a novel MyoAAV capsid to deliver a functional copy of the MTM1 gene for the treatment of X-linked myotubular myopathy
Ref: PRNewswire | Image: Astellas
Related News:- Astellas’ Veozah (fezolinetant) Receives the US FDA’s Approval for the Treatment of Vasomotor Symptoms Due to Menopause
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
